Pfizer Inc. $PFE Shares Bought by Lombard Odier Asset Management Switzerland SA

Lombard Odier Asset Management Switzerland SA lifted its holdings in Pfizer Inc. (NYSE:PFE) by 1,250.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 185,193 shares of the biopharmaceutical company’s stock after acquiring an additional 171,477 shares during the quarter. Lombard Odier Asset Management Switzerland SA’s holdings in Pfizer were worth $4,611,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Atom Investors LP grew its holdings in shares of Pfizer by 242.7% in the 4th quarter. Atom Investors LP now owns 167,271 shares of the biopharmaceutical company’s stock worth $4,165,000 after acquiring an additional 118,463 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Pfizer in the 4th quarter worth $56,000. ExodusPoint Capital Management LP grew its holdings in shares of Pfizer by 203.1% in the 4th quarter. ExodusPoint Capital Management LP now owns 1,482,551 shares of the biopharmaceutical company’s stock worth $36,916,000 after acquiring an additional 993,496 shares during the last quarter. Fullerton Fund Management Co Ltd. acquired a new position in shares of Pfizer in the 4th quarter worth $325,000. Finally, Howe & Rusling Inc. grew its holdings in shares of Pfizer by 34.3% in the 4th quarter. Howe & Rusling Inc. now owns 41,068 shares of the biopharmaceutical company’s stock worth $1,023,000 after acquiring an additional 10,488 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s obesity pipeline gained traction after detailed Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and low reported adverse events. Pfizer has already moved the program into Phase 3, which could support longer-term growth expectations. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: CEO comments that Pfizer could return to high-single-digit growth suggest the business may be stabilizing faster than some investors expected, reinforcing the idea that the company’s recent weakness may be overdone. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Neutral Sentiment: Pfizer is drawing heavy investor interest and analyst coverage, with recent research pieces focusing on its discounted valuation, pipeline prospects, and post-COVID growth outlook. That keeps sentiment active, but the articles do not point to a single new catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Pfizer also remained in the news through broader healthcare coverage and research roundups, but these items appear informational rather than stock-moving. Top Research Reports for Pfizer, Altria & Newmont Corp.
• Negative Sentiment: Some coverage continues to frame Pfizer as a value stock facing fading COVID revenue and looming patent-cliff pressure, which reminds investors of the company’s near-term growth challenges even as pipeline efforts progress. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PFE shares. HSBC lifted their target price on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Barclays assumed coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price on the stock. UBS Group reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Cantor Fitzgerald reissued a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Finally, Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.82.

Pfizer Stock Performance

Shares of PFE stock opened at $26.04 on Wednesday. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $148.41 billion, a price-to-earnings ratio of 19.88 and a beta of 0.34. The stock’s fifty day simple moving average is $26.34 and its 200-day simple moving average is $26.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the company posted $0.92 earnings per share. Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s payout ratio is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.